Especially midrange hormone receptor positive breast cancers may pose diagnostic challenges, as the indication for or against adjuvant chemotherapy cannot be met upon traditional clinic-pathological parameters in all instances [1–3]. This evidence concerns the gene NR4A1 and breast cancer.